Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: Their prevalence and molecular correlates

Acta Neuropathologica

Volumn 127, Issue 5, 2014, Pages 747-759

  Kastenhuber, Edward R ^a   Huse, Jason T ^a   Berman, Samuel H ^a   Pedraza, Alicia ^a   Zhang, Jianan ^a   Suehara, Yoshiyuki ^a   Viale, Agnes ^a   Cavatore, Magali ^a   Heguy, Adriana ^a   Szerlip, Nicholas ^b   Ladanyi, Marc ^a   Brennan, Cameron W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFRvIII; GBM; Glioblastoma; Nanostring; RNA sequencing; TCGA

Indexed keywords

MESSENGER RNA; RNA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; PROTEIN TYROSINE KINASE;

ARTICLE; EGFRV GENE; EGFRVII GENE; EGFRVIII GENE; GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; PDGFRA GENE; PREVALENCE; PRIORITY JOURNAL; PROTEIN TYROSINE KINASE GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; BRAIN NEOPLASMS; COPY NUMBER VARIATION; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MUTATION; PROCEDURES; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SURVIVAL;

BRAIN NEOPLASMS; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; MUTATION; PREVALENCE; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA; SEQUENCE DELETION; SURVIVAL ANALYSIS;

EID: 84899946668     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1217-3     Document Type: Article

References (51)

1. Al-Nedawi K, Meehan B, Micallef J et al (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10:619-624. doi:10.1038/ncb1725 (Pubitemid 351627382)
2. Aldape KD, Ballman K, Furth A et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700-707 (Pubitemid 38891086)
3. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H (2004) Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14:131-136 (Pubitemid 38656384)
4. Brennan C, Momota H, Hambardzumyan D et al (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752. doi:10.1371/journal.pone.0007752
5. Brennan CW, Verhaak RG, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462-477. doi:10.1016/j.cell.2013.09.034
6. Chen WS, Lazar CS, Lund KA et al (1989) Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell 59:33-43 (Pubitemid 19248556)
7. Cho J, Pastorino S, Zeng Q et al (2011) Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res 71:7587-7596. doi:10.1158/0008-5472.CAN-11-0821
8. Dunn GP, Rinne ML, Wykosky J et al (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26:756-784. doi:10.1101/gad.187922.112
9. Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89:4309-4313
10. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387 (Pubitemid 30152011)
11. Gajadhar AS, Bogdanovic E, Munoz DM, Guha A (2012) In Situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol Cancer Res 10:428-440. doi:10.1158/1541-7786.MCR-11-0531
12. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748-754. doi:10.1016/j.jocn.2008.12.005
13. Geiss GK, Bumgarner RE, Birditt B et al (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317-325. doi:10.1038/nbt1385 (Pubitemid 351355126)
14. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS (2007) EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28:1408-1417. doi:10.1093/carcin/bgm058 (Pubitemid 47241789)
15. Heimberger AB, Hlatky R, Suki D et al (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462-1466. doi:10.1158/1078-0432.CCR-04-1737 (Pubitemid 40315227)
16. Horvath S, Zhang B, Carlson M et al (2006) Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA 103:17402-17407. doi:10.1073/pnas.0608396103 (Pubitemid 44788981)
17. Huang PH, Mukasa A, Bonavia R et al (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104:12867-12872. doi:10.1073/pnas.0705158104 (Pubitemid 47255246)
18. Huse JT, Holland E, Deangelis LM (2013) Glioblastoma: molecular analysis and clinical implications. Annu Rev Med 64:59-70. doi:10.1146/annurev-med- 100711-143028
19. Inda MM, Bonavia R, Mukasa A et al (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24:1731-1745. doi:10.1101/gad.1890510
20. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96 (Pubitemid 32641351)
21. Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T (1992) Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. Oncogene 7:627-633
22. Lal A, Glazer CA, Martinson HM et al (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335-3339 (Pubitemid 34651373)
23. Lee JC, Vivanco I, Beroukhim R et al (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3:e485. doi:10.1371/journal.pmed.0030485
24. Liu L, Backlund LM, Nilsson BR et al (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83:917-926. doi:10.1007/s00109-005-0700-2 (Pubitemid 41598692)
25. Luwor RB, Zhu HJ, Walker F et al (2004) The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23:6095-6104. doi:10.1038/sj.onc.1207870 (Pubitemid 39178862)
26. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024. doi:10.1056/NEJMoa051918 (Pubitemid 41609094)
27. Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF (2012) Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol 355:135-169. doi:10.1007/82-2011-178
28. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277:301-308. doi:10.1111/j.1742-4658.2009.07448.x
29. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65:1181-1188. doi:10.1097/01.jnen.0000248549.14962.b2 (Pubitemid 44885942)
30. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086 (Pubitemid 26374452)
31. Network T (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068. doi:10.1038/ nature07385
32. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12:7261-7270. doi:10.1158/1078-0432.CCR-06- 0874 (Pubitemid 46095397)
33. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M (2004) Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 21:53-56 (Pubitemid 39518146)
34. Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522. doi:10.1016/j.ccr.2010.03.017
35. Okada H, Kohanbash G, Zhu X et al (2009) Immunotherapeutic approaches for glioma. Crit Rev Immunol 29:1-42
36. Ozawa T, Brennan CW, Wang L et al (2010) PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 24:2205-2218. doi:10.1101/gad.1972310
37. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173. doi:10.1016/j.ccr.2006.02.019 (Pubitemid 43357943)
38. Pines G, Huang PH, Zwang Y, White FM, Yarden Y (2010) EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase auto-inhibitory mechanism. Oncogene 29:5850-5860. doi:10.1038/onc.2010.313
39. Prigent SA, Nagane M, Lin H et al (1996) Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271:25639-25645 (Pubitemid 26337944)
40. Rand V, Huang J, Stockwell T et al (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 102:14344-14349. doi:10.1073/pnas.0507200102 (Pubitemid 41429700)
41. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3 Doi: 10.2202/1544-6115.1027
42. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602-8606
43. Szerlip NJ, Pedraza A, Chakravarty D et al (2012) Intra-tumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 109:3041-3046. doi:10.1073/pnas.1114033109
44. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068. doi:10.1038/ nature07385
45. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110. doi:10.1016/j.ccr.2009.12.020
46. Vivanco I, Robins HI, Rohle D et al (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-471. doi:10.1158/2159-8290.CD-11-0284
47. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197-1206 (Pubitemid 28164074)
48. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG (1990) Ligand-induced transformation by a non-internalizing epidermal growth factor receptor. Science 247:962-964
49. Wiedemeyer R, Brennan C, Heffernan TP et al (2008) Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 13:355-364. doi:10.1016/j.ccr.2008.02.010 (Pubitemid 351454058)
50. Wu JL, Abe T, Inoue R, Fujiki M, Kobayashi H (2004) Ikappa-BalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells. Neurol Res 26:785-791. doi:10.1179/ 016164104225014139 (Pubitemid 39552727)
51. Yoshimoto K, Dang J, Zhu S et al (2008) Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 14:488-493. doi:10.1158/1078-0432.CCR-07-1966 (Pubitemid 351226117)